Abstract:The evolution of drug resistance in fungal pathogens compromises the efficacy of the limited number of antifungal drugs. Drug combinations have emerged as a powerful strategy to enhance antifungal efficacy and abrogate drug resistance, but the impact on the evolution of drug resistance remains largely unexplored. Targeting the molecular chaperone Hsp90 or its downstream effector, the protein phosphatase calcineurin, abrogates resistance to the most widely deployed antifungals, the azoles, which inhibit ergosterol biosynthesis. Here, we evolved experimental populations of the model yeast Saccharomyces cerevisiae and the leading human fungal pathogen Candida albicans with azole and an inhibitor of Hsp90, geldanamycin, or calcineurin, FK506. To recapitulate a clinical context where Hsp90 or calcineurin inhibitors could be utilized in combination with azoles to render resistant pathogens responsive to treatment, the evolution experiment was initiated with strains that are resistant to azoles in a manner that depends on Hsp90 and calcineurin. Of the 290 lineages initiated, most went extinct, yet 14 evolved resistance to the drug combination. Drug target mutations that conferred resistance to geldanamycin or FK506 were identified and validated in five evolved lineages. Whole-genome sequencing identified mutations in a gene encoding a transcriptional activator of drug efflux pumps, PDR1, and a gene encoding a transcriptional repressor of ergosterol biosynthesis genes, MOT3, that transformed azole resistance of two lineages from dependent on calcineurin to independent of this regulator. Resistance also arose by mutation that truncated the catalytic subunit of calcineurin, and by mutation in LCB1, encoding a sphingolipid biosynthetic enzyme. Genome analysis revealed extensive aneuploidy in four of the C. albicans lineages. Thus, we identify molecular determinants of the transition of azole resistance from calcineurin dependence to independence and establish multiple mechanisms by which resistance to drug combinations evolves, providing a foundation for predicting and preventing the evolution of drug resistance.

Collateral sensitivity counteracts the evolution of antifungal drug resistance in Candida auris

Collateral Sensitivity Between Tetracyclines and Aminoglycosides Constrains Resistance Evolution in Carbapenem-Resistant Klebsiella Pneumoniae.

Efficacy of the combination of amphotericin B and echinocandins against Candida auris in vitro and in the Caenorhabditis elegans host model

Backward collateral sensitivity can restore antibiotic susceptibility

Genetic and Genomic Architecture of the Evolution of Resistance to Antifungal Drug Combinations

Synergistic Combinations of Antifungals and Anti-Virulence Agents to Fight Againstcandida Albicans

Genetic microevolution of clinical Candida auris with reduced Amphotericin B sensitivity in China

What makes Candida auris pan-drug resistant? Integrative insights from genomic, transcriptomic, and phenomic analysis of clinical strains resistant to all four major classes of antifungal drugs

Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond.

Current Perspectives of Antifungal Therapy: A Special Focus on Candida auris

The evolution of antibiotic resistance is associated with collateral drug phenotypes in Mycobacterium tuberculosis

Optimising the Treatment of Invasive Candidiasis – A Case for Combination Therapy

Recent gene selection and drug resistance underscore clinical adaptation across Candida species

Small molecules for combating multidrug-resistant superbug Candida auris infections.

Collateral Sensitivity to β-Lactam Antibiotics in Evolved Apramycin-Resistant MRSA

Molecular mechanisms underlying the emergence of polygenetic antifungal drug resistance in msh2 mismatch repair mutants of Cryptococcus

An Insight into New Strategies to Combat Antifungal Drug Resistance

Evolutionary accumulation of FKS 1 mutations from clinical echinocandin-resistant Candida auris

A correlative study of the genomic underpinning of virulence traits and drug tolerance of Candida auris

Pharmacodynamic considerations of collateral sensitivity in design of antibiotic treatment regimen

A Systematic Screen Reveals a Diverse Collection of Medications That Induce Antifungal Resistance in Candida Species